KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
September 6, 2024 6:35 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "Bottom Line: We are updating our model following the disclosure of KALV's F1Q financial results and corporate update; the FDA recently accepted sebetralstat's NDA with a PDUFA goal date of June 17, 2025. The company continues to advance lead asset sebetralstat (KVD900), an oral plasma kallikrein inhibitor, towards a commercial launch for the on-demand treatment of... More
